Retatrutide is a next-generation triple-receptor agonist available through Peptigain, developed to simultaneously activate three key hormonal pathways — GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and the Glucagon receptor. This triple-action mechanism positions it as one of the most powerful metabolic research peptides in the current scientific landscape, surpassing the dual-agonist profile of earlier generation compounds.

Peptigain's Retatrutide offers researchers a multi-targeted approach to metabolic health: GLP-1 suppresses appetite and slows gastric emptying, GIP enhances insulin sensitivity and energy partitioning, while glucagon receptor activation accelerates energy expenditure and hepatic fat metabolism. Phase 2 clinical research has demonstrated up to 24% body weight reduction — the highest reported figure in its compound class at the time of study.